PCI Biotech Holding ASA (OSL:PCIB)

Norway flag Norway · Delayed Price · Currency is NOK
0.138
+0.003 (1.85%)
At close: Feb 27, 2026
-91.38%
Market Cap 5.15M
Revenue (ttm) 4.69M
Net Income (ttm) -20.54M
Shares Out 37.33M
EPS (ttm) -0.55
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 65,178
Average Volume 439,815
Open 0.136
Previous Close 0.136
Day's Range 0.136 - 0.160
52-Week Range 0.090 - 2.220
Beta 1.23
RSI 32.01
Earnings Date Feb 17, 2026

About PCI Biotech Holding ASA

PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development of technologies and novel therapies through its photochemical technology platform. The company’s technology platform consists of a proprietary small molecule photosensitiser and a light source; and develops photochemical lysis (PCL) comprising light-triggered cell lysis, which enhances yield and purity in viral vector manufacturing, as well as photochemical internalisation (PCI), inducing light-triggered intracellular release for various therapeutic modalities. It ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2007
Employees 5
Stock Exchange Oslo Børs
Ticker Symbol PCIB
Full Company Profile

Financial Performance

In 2024, PCI Biotech Holding ASA's revenue was 6.74 million, an increase of 125.25% compared to the previous year's 2.99 million. Losses were -16.42 million, -19.19% less than in 2023.

Financial Statements

News

There is no news available yet.